Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Laxmi Dental
Quarter-by-quarter operating performance
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 48 | 55 | 60 | 57 | 62 | 61 | 66 | 72 | 66 | 74 |
| Expenses + | 44 | 43 | 46 | 48 | 52 | 51 | 54 | 61 | 59 | 60 |
| Operating Profit | 4 | 12 | 14 | 9 | 10 | 10 | 12 | 11 | 7 | 14 |
| OPM % | 8% | 21% | 23% | 15% | 16% | 16% | 18% | 15% | 11% | 18% |
| Other Income + | -0 | -0 | 6 | 1 | 1 | 2 | 2 | 2 | -4 | 2 |
| Interest | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | -1 | 7 | 16 | 5 | 5 | 6 | 10 | 9 | -1 | 11 |
| Tax % | -140% | 16% | 11% | 23% | 23% | 41% | 24% | 20% | -175% | 4% |
| Net Profit + | 2 | 8 | 17 | 6 | 5 | 4 | 8 | 9 | 2 | 10 |
| EPS in Rs | 74.05 | 243.91 | 6.04 | 2.12 | 0.93 | 0.78 | 1.53 | 1.55 | 0.36 | 1.83 |
Financials of Laxmi Dental
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 150 | 92 | 137 | 162 | 194 | 239 | 278 |
| Expenses + | 146 | 88 | 130 | 152 | 169 | 196 | 234 |
| Operating Profit | 3 | 4 | 7 | 9 | 24 | 43 | 43 |
| OPM % | 2% | 5% | 5% | 6% | 13% | 18% | 16% |
| Other Income + | 2 | 0 | -10 | 2 | 0 | 10 | 3 |
| Interest | 3 | 3 | 4 | 4 | 6 | 6 | 1 |
| Depreciation | 7 | 6 | 8 | 11 | 12 | 15 | 16 |
| Profit before tax | -4 | -4 | -16 | -5 | 7 | 31 | 29 |
| Tax % | 5% | 8% | 15% | 4% | -136% | 21% | 9% |
| Net Profit + | -5 | -5 | -19 | -4 | 25 | 32 | 29 |
| EPS in Rs | -154.92 | -156.22 | -596.62 | -128.94 | 804.81 | 5.78 | 5.27 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Laxmi Dental
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 11 | 11 |
| Reserves | 37 | 33 | 9 | 6 | 31 | 198 | 232 |
| Borrowings + | 37 | 39 | 50 | 50 | 61 | 20 | 13 |
| Other Liabilities + | 31 | 34 | 43 | 40 | 46 | 60 | 38 |
| Total Liabilities | 106 | 106 | 103 | 97 | 139 | 288 | 294 |
| Fixed Assets + | 39 | 42 | 40 | 40 | 46 | 51 | 63 |
| CWIP | 0 | 7 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 6 | 10 | 27 |
| Other Assets + | 66 | 56 | 63 | 56 | 87 | 227 | 204 |
| Total Assets | 106 | 106 | 103 | 97 | 139 | 288 | 294 |
Financials of Laxmi Dental
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 12 | 10 | -2 | 14 | 8 | 44 | -5 |
| Cash from Investing Activity + | -18 | -9 | 3 | -10 | -11 | -29 | -80 |
| Cash from Financing Activity + | 6 | -0 | -4 | -1 | -3 | 111 | -18 |
| Net Cash Flow | 0 | 0 | -3 | 3 | -5 | 125 | -102 |
| Free Cash Flow | -5 | 0 | -0 | 5 | -5 | 28 | -23 |
| CFO/OP | 357% | 226% | -30% | 157% | 38% | 109% | 4% |
Financials of Laxmi Dental
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 64 | 54 | 46 | 47 | 56 | 60 |
| Inventory Days | 186 | 305 | 272 | 212 | 397 | 97 | |
| Days Payable | 197 | 273 | 245 | 197 | 585 | 47 | |
| Cash Conversion Cycle | 54 | 96 | 81 | 61 | 47 | -132 | 109 |
| Working Capital Days | 13 | 3 | -3 | -13 | 0 | 37 | 195 |
| ROCE % | 3% | -1% | 1% | 18% | 19% | 15% |
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…
Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…
Tarsons has undertaken a significant capex of INR 600 crores announced in 2021-22, with partial commercialization in 2026. Key concall takeaways from Tarsons…